Zondor Stacey D, George James N, Medina Patrick J
College of Pharmacy, Department of Pharmacy, University of Oklahoma Health Sciences Center, 1110 North Stonewall, Post Office Box 26901, Oklahoma City, OK 73190-5040, USA.
Expert Opin Drug Saf. 2002 Jul;1(2):173-80. doi: 10.1517/14740338.1.2.173.
Estimates on the incidence of drug-induced thrombocytopenia range 5-40% in patients receiving heparin to < 1% with other causative agents. Systematically assessing drug-induced thrombocytopenia through a series of steps, each step providing additional evidence that the suspected agent is the true cause of thrombocytopenia, is the best way to identify the causative agent. Databases exist to aid in identification of the causative agent. Knowing which medications may be causative agents as well as which are not known to cause drug-induced thrombocytopenia, the aetiologies of drug-induced thrombocytopenia, signs and symptoms of thrombocytopenia and strategies to treat thrombocytopenia associated with specific agents will provide the clinician with the necessary skills to make proper medical decisions.
接受肝素治疗的患者中,药物性血小板减少症的发生率估计为5%-40%,而使用其他致病药物时发生率则低于1%。通过一系列步骤系统地评估药物性血小板减少症,每一步都提供额外证据证明可疑药物是血小板减少症的真正病因,这是识别致病药物的最佳方法。现有数据库可协助识别致病药物。了解哪些药物可能是致病药物、哪些药物不会导致药物性血小板减少症、药物性血小板减少症的病因、血小板减少症的体征和症状以及治疗与特定药物相关的血小板减少症的策略,将为临床医生提供做出正确医疗决策所需的技能。